Ampio subsidiary Vyrix files for IPO

The Vyrix Pharmaceutical Inc. subsidiary of Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) filed to raise up to $28.8 million in an IPO on NYSE MKT. Aegis Capital and Fordham are underwriters. Ampio carved off its sexual dysfunction business into Vyrix in December. Vyrix's lead product is Zertane tramadol, an oral fast-dissolving tablet formulation of tramadol hydrochloride in development for premature ejaculation (PE). Next half, Vyrix plans to submit an IND for a pair of U.S. Phase III trials, with the goal of starting the trials "soon after the IND becomes effective." ...